Treatment strategies in axial spondyloarthritis: what, when and how?

Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa

(2020) Maria C. Schneeweiss et al.   JAMA Dermatology

The Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta‐Analysis

(2020) Paras Karmacharya et al.   Arthritis & Rheumatology

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review

(2020) Xenofon Baraliakos et al.   Therapeutic Advances in Musculoskeletal Disease

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

(2020) Iain B McInnes et al.   LANCET

High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients

(2019) Silje Halvorsen Sveaas et al.   BRITISH JOURNAL OF SPORTS MEDICINE

Pharmacology, efficacy and safety of JAK inhibitors in Crohn’s disease

(2019) Christopher Ma et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

(2019) Stefan Schreiber et al.   ANNALS OF THE RHEUMATIC DISEASES

Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment

(2019) George E Fragoulis et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression

(2019) Richard James Cuthbert et al.   ANNALS OF THE RHEUMATIC DISEASES

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial

(2019) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review

(2019) Nadine Boers et al.   RHEUMATOLOGY

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2019) Michael M. Ward et al.   Arthritis & Rheumatology

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

(2019) April Armstrong et al.   Dermatology and Therapy

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

(2019) Désirée van der Heijde et al.   LANCET

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

(2019) Atul Deodhar et al.   LANCET

Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis

(2018) Runsheng Wang et al.   JOURNAL OF RHEUMATOLOGY

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

(2018) Paul Emery et al.   PHARMACOECONOMICS

High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: A possible new extra-articular manifestation

(2018) Angelique Rondags et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Impact of tumour necrosis factor inhibitor versus non-steroidal anti-inflammatory drug treatment on radiographic progression in early ankylosing spondylitis: Its relationship to inflammation control during treatment

(2018) Jun Won Park et al.   Arthritis & Rheumatology

The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling

(2018) Melissa N. van Tok et al.   Frontiers in Immunology

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

(2018) Dominique Baeten et al.   ANNALS OF THE RHEUMATIC DISEASES

Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease

(2018) Sayam Dubash et al.   RHEUMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?

(2018) Stefan Siebert et al.   ANNALS OF THE RHEUMATIC DISEASES

Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study

(2018) Rianne E. van Bentum et al.   JOURNAL OF RHEUMATOLOGY

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

(2018) Désirée van der Heijde et al.   LANCET

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study

(2018) Jürgen Braun et al.   RHEUMATOLOGY

IL-17A Inhibition Diminishes Inflammation and New Bone Formation In Experimental Spondyloarthritis

(2018) Melissa N. van Tok et al.   Arthritis & Rheumatology

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis

(2017) Ennio Lubrano et al.   JOURNAL OF RHEUMATOLOGY

Enthesitis: from pathophysiology to treatment

(2017) Georg Schett et al.   Nature Reviews Rheumatology

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treat to Target in Axial Spondyloarthritis: What Are the Issues?

(2017) Abhijeet Danve et al.   Current Rheumatology Reports

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

(2016) Stephan R Targan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort

(2016) Denis Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases

(2016) George E. Fragoulis et al.   Annual Review of Medicine

Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry

(2016) Bente Glintborg et al.   JOURNAL OF RHEUMATOLOGY

Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review

(2016) F. P. B. Kroon et al.   JOURNAL OF RHEUMATOLOGY

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis

(2016) Xenofon Baraliakos et al.   RHEUMATOLOGY

Benefit of health education by a training nurse in patients with axial and/or peripheral psoriatic arthritis: A systematic literature review

(2016) G. Candelas et al.   RHEUMATOLOGY INTERNATIONAL

Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis—3-Year data of the ESTHER trial

(2016) In-Ho Song et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Acti

(2016) Denis Poddubnyy et al.   Arthritis & Rheumatology

Brief Report: Six-Week Treatment of Axial Spondyloarthritis Patients With an Optimal Dose of Nonsteroidal Antiinflammatory Drugs: Early Response to Treatment in Signal Intensity on Magnetic Resonance Imaging of the Sacroiliac Joints

(2016) G. Varkas et al.   Arthritis & Rheumatology

Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality

(2015) Nisha Nigil Haroon et al.   ANNALS OF INTERNAL MEDICINE

Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)

(2015) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study

(2015) Xenofon Baraliakos et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for patient education for people with inflammatory arthritis

(2015) Heidi A Zangi et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study

(2015) Walter P Maksymowych et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study

(2014) Ivette Essers et al.   ANNALS OF THE RHEUMATIC DISEASES

Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort

(2014) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis

(2014) Johanna Callhoff et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database

(2014) Daniel Wendling et al.   CURRENT MEDICAL RESEARCH AND OPINION

Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS

(2014) I. Essers et al.   RHEUMATOLOGY

Body weight, gender and response to TNF-  blockers in axial spondyloarthritis

(2014) E. Gremese et al.   RHEUMATOLOGY

Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study

(2014) Maxime Dougados et al.   ARTHRITIS RESEARCH & THERAPY

Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2

(2013) J Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1

(2013) J Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study

(2013) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Tumor Necrosis Factor α Inhibition in Radiographic and Nonradiographic Axial Spondyloarthritis: Results From a Large Observational Cohort

(2013) Adrian Ciurea et al.   ARTHRITIS AND RHEUMATISM

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials

(2013) Andrew D. Dick et al.   OPHTHALMOLOGY

Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification

(2012) Walter P Maksymowych et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

(2012) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis

(2012) Féline Kroon et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort

(2012) Denis Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study

(2012) M. Dougados et al.   RHEUMATOLOGY

Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?

(2012) Uta Kiltz et al.   ARTHRITIS CARE & RESEARCH

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial

(2011) I.-H. Song et al.   ANNALS OF THE RHEUMATIC DISEASES

Increased mortality in ankylosing spondylitis is related to disease activity

(2011) G. Bakland et al.   ANNALS OF THE RHEUMATIC DISEASES

Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort

(2011) Ho Yin Chung et al.   ANNALS OF THE RHEUMATIC DISEASES

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis

(2011) Denis Poddubnyy et al.   ARTHRITIS AND RHEUMATISM

Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis

(2009) Nick Barkham et al.   ARTHRITIS AND RHEUMATISM

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two

(2008) Hildrun Haibel et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

(2008) Robert D. Inman et al.   ARTHRITIS AND RHEUMATISM

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis

(2008) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept

(2008) D. van der Heijde et al.   ARTHRITIS AND RHEUMATISM